Skip to main content
SpringerLink
Log in

Medical Treatment of GERD

  • Chapter
  • First Online:
Foregut Surgery

Abstract

Medical therapy for gastroesophageal reflux disease (GERD) may be approached in two ways: directly applied to correct the underlying mechanisms involved in disease pathogenesis or alternatively applied to symptom severity in a “step-up” or “step-down” fashion. Mechanistic approaches to therapy can further be subdivided into directing therapy at decreasing the frequency of transient lower esophageal sphincter relaxation to minimize esophageal exposure to gastric acid or more commonly neutralizing or suppressing gastric acidity, thereby rendering refluxed materials less caustic to esophageal mucosa. Pharmacologic agents for patients with persistent symptoms despite lifestyle interventions include nonabsorbable agents, antisecretory agents, prokinetic agents, and inhibitors of transient lower esophageal sphincter relaxations (TLESRs).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology. 2000;118(2):S9–S31.

    Article  CAS  PubMed  Google Scholar 

  2. Kroch DA, Madanick RD. Medical treatment of gastroesophageal reflux disease. World J Surg. 2017;41(7):1678–84.

    Article  PubMed  Google Scholar 

  3. Kahrilas PJ, Shaheen NJ, Vaezi MF, Institute AGA, Committee CPaQM. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135(4):1392–413, 413.e1–5

    Article  PubMed  Google Scholar 

  4. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108(3):308–28.. quiz 29

    Article  PubMed  Google Scholar 

  5. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166(9):965–71.

    Article  PubMed  Google Scholar 

  6. Dua K, Bardan E, Ren J, Sui Z, Shaker R. Effect of chronic and acute cigarette smoking on the pharyngo-upper oesophageal sphincter contractile reflex and reflexive pharyngeal swallow. Gut. 1998;43(4):537–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Stanciu C, Bennett JR. Smoking and gastro-oesophageal reflux. Br Med J. 1972;3(5830):793–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol. 2000;95(12):3374–82.

    Article  CAS  PubMed  Google Scholar 

  9. Grande L, Monforte R, Ros E, Toledo-Pimentel V, Estruch R, Lacima G, et al. High amplitude contractions in the middle third of the oesophagus: a manometric marker of chronic alcoholism? Gut. 1996;38(5):655–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cranley JP, Achkar E, Fleshler B. Abnormal lower esophageal sphincter pressure responses in patients with orange juice-induced heartburn. Am J Gastroenterol. 1986;81(2):104–6.

    CAS  PubMed  Google Scholar 

  11. Thomas FB, Steinbaugh JT, Fromkes JJ, Mekhjian HS, Caldwell JH. Inhibitory effect of coffee on lower esophageal sphincter pressure. Gastroenterology. 1980;79(6):1262–6.

    Article  CAS  PubMed  Google Scholar 

  12. Wright LE, Castell DO. The adverse effect of chocolate on lower esophageal sphincter pressure. Am J Dig Dis. 1975;20(8):703–7.

    Article  CAS  PubMed  Google Scholar 

  13. Nebel OT, Castell DO. Inhibition of the lower oesophageal sphincter by fat–a mechanism for fatty food intolerance. Gut. 1973;14(4):270–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kadakia SC, Kikendall JW, Maydonovitch C, Johnson LF. Effect of cigarette smoking on gastroesophageal reflux measured by 24-h ambulatory esophageal pH monitoring. Am J Gastroenterol. 1995;90(10):1785–90.

    CAS  PubMed  Google Scholar 

  15. Pehl C, Pfeiffer A, Wendl B, Kaess H. The effect of decaffeination of coffee on gastro-oesophageal reflux in patients with reflux disease. Aliment Pharmacol Ther. 1997;11(3):483–6.

    Article  CAS  PubMed  Google Scholar 

  16. Wendl B, Pfeiffer A, Pehl C, Schmidt T, Kaess H. Effect of decaffeination of coffee or tea on gastro-oesophageal reflux. Aliment Pharmacol Ther. 1994;8(3):283–7.

    Article  CAS  PubMed  Google Scholar 

  17. Murphy DW, Castell DO. Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am J Gastroenterol. 1988;83(6):633–6.

    CAS  PubMed  Google Scholar 

  18. Allen ML, Mellow MH, Robinson MG, Orr WC. The effect of raw onions on acid reflux and reflux symptoms. Am J Gastroenterol. 1990;85(4):377–80.

    CAS  PubMed  Google Scholar 

  19. Iwakiri K, Kobayashi M, Kotoyori M, Yamada H, Sugiura T, Nakagawa Y. Relationship between postprandial esophageal acid exposure and meal volume and fat content. Dig Dis Sci. 1996;41(5):926–30.

    Article  CAS  PubMed  Google Scholar 

  20. Hamilton JW, Boisen RJ, Yamamoto DT, Wagner JL, Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988;33(5):518–22.

    Article  CAS  PubMed  Google Scholar 

  21. Pollmann H, Zillessen E, Pohl J, Rosemeyer D, Abucar A, Armbrecht U, et al. Effect of elevated head position in bed in therapy of gastroesophageal reflux. Z Gastroenterol. 1996;34 Suppl 2:93–9.

    Google Scholar 

  22. Harvey RF, Gordon PC, Hadley N, Long DE, Gill TR, Macpherson RI, et al. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet. 1987;2(8569):1200–3.

    Article  CAS  PubMed  Google Scholar 

  23. Duroux P, Bauerfeind P, Emde C, Koelz HR, Blum AL. Early dinner reduces nocturnal gastric acidity. Gut. 1989;30(8):1063–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Orr WC, Harnish MJ. Sleep-related gastro-oesophageal reflux: provocation with a late evening meal and treatment with acid suppression. Aliment Pharmacol Ther. 1998;12(10):1033–8.

    Article  CAS  PubMed  Google Scholar 

  25. Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130(3):639–49.

    Article  PubMed  Google Scholar 

  26. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354(22):2340–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211.

    Article  PubMed  Google Scholar 

  28. Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol. 2013;108(3):376–82.

    Article  PubMed  Google Scholar 

  29. Mathus-Vliegen LM, Tytgat GN. Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension. Eur J Gastroenterol Hepatol. 1996;8(7):635–40.

    CAS  PubMed  Google Scholar 

  30. Mathus-Vliegen EM, Tygat GN. Gastro-oesophageal reflux in obese subjects: influence of overweight, weight loss and chronic gastric balloon distension. Scand J Gastroenterol. 2002;37(11):1246–52.

    Article  CAS  PubMed  Google Scholar 

  31. Mathus-Vliegen EM, van Weeren M, van Eerten PV. Los function and obesity: the impact of untreated obesity, weight loss, and chronic gastric balloon distension. Digestion. 2003;68(2–3):161–8.

    Article  CAS  PubMed  Google Scholar 

  32. Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol. 1999;34(4):337–40.

    Article  CAS  PubMed  Google Scholar 

  33. Kjellin A, Ramel S, Rössner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol. 1996;31(11):1047–51.

    Article  CAS  PubMed  Google Scholar 

  34. Singh M, Lee J, Gupta N, Gaddam S, Smith BK, Wani SB, et al. Weight loss can lead to resolution of gastroesophageal reflux disease symptoms: a prospective intervention trial. Obesity (Silver Spring). 2013;21(2):284–90.

    Article  Google Scholar 

  35. Sontag SJ. The medical-management of reflux esophagitis – role of antacids and acid inhibition. Gastroenterol Clin N. 1990;19(3):683–712.

    CAS  Google Scholar 

  36. Decktor DL, Robinson M, Maton PN, Lanza FL, Gottlieb S. Effects of aluminum/magnesium hydroxide and calcium carbonate on esophageal and gastric pH in subjects with heartburn. Am J Ther. 1995;2(8):546–52.

    Article  PubMed  Google Scholar 

  37. Decktor DL, Robinson M, Gottlieb S. Comparative effects of liquid antacids on esophageal and gastric pH in patients with heartburn. Am J Ther. 1995;2(7):481–6.

    Article  PubMed  Google Scholar 

  38. McRorie JW Jr, Gibb RD, Miner PB Jr. Evidence-based treatment of frequent heartburn: the benefits and limitations of over-the-counter medications. J Am Assoc Nurse Pract. 2014;26(6):330–9.

    PubMed  Google Scholar 

  39. Maton PN, Burton ME. Antacids revisited – a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999;57(6):855–70.

    Article  CAS  PubMed  Google Scholar 

  40. Collings KL, Rodriguez-Stanley S, Proskin HM, Robinson M, Miner PB. Clinical effectiveness of a new antacid chewing gum on heartburn and oesophageal pH control. Aliment Pharm Therap. 2002;16(12):2029–35.

    Article  CAS  Google Scholar 

  41. Robinson M, Rodriguez-Stanley S, Miner PB, McGuire AJ, Fung K, Ciociola AA. Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn. Aliment Pharm Therap. 2002;16(3):435–43.

    Article  CAS  Google Scholar 

  42. Grove O, Bekker C, Jeppe-Hansen MG, Karstoft E, Sanchez G, Axelsson CK, et al. Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial. Scand J Gastroenterol. 1985;20(4):457–61.

    Article  CAS  PubMed  Google Scholar 

  43. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol. 1989;24(4):401–6.

    Article  CAS  PubMed  Google Scholar 

  44. Graham DY, Patterson DJ. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983;28(6):559–63.

    Article  CAS  PubMed  Google Scholar 

  45. Petrokubi RJ, Jeffries GH. Cimetidine versus antacid in scleroderma with reflux esophagitis – randomized double-blind controlled-study. Gastroenterology. 1979;77(4):691–5.

    Article  CAS  PubMed  Google Scholar 

  46. Cucchiara S, Staiano A, Romaniello G, Capobianco S, Auricchio S. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child. 1984;59(9):842–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Houcke P, Maffioli C, Corallo J, Bouxin-Sauzet A, Martin AL. Comparison of the effects of Rocgel and anti-H2 on the symptomatology of gastroesophageal reflux without esophagitis. Ann Gastroenterol Hepatol (Paris). 1995;31(4):264–7.

    CAS  Google Scholar 

  48. Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(5):1–9.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Manabe N, Haruma K, Ito M, Takahashi N, Takasugi H, Wada Y, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus. 2012;25(5):373–80.

    Article  CAS  PubMed  Google Scholar 

  50. Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharm Therap. 2010;32(3):334–43.

    Article  CAS  Google Scholar 

  51. Kessing BF, Conchillo JM, Bredenoord AJ, Smout AJPM, Masclee AAM. Review article: the clinical relevance of transient lower oesophageal sphincter relaxations in gastro-oesophageal reflux disease. Aliment Pharm Therap. 2011;33(6):650–61.

    Article  CAS  Google Scholar 

  52. Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a meta-analysis of randomized controlled trials. Gastroenterol Res Pract. 2014;2014:307805.

    PubMed  PubMed Central  Google Scholar 

  53. Koek GH, Sifrim D, Lerut T, Janssens J, Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. 2003;52(10):1397–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. Best Pract Res Clin Gastroenterol. 2001;15(3):355–70.

    Article  CAS  PubMed  Google Scholar 

  55. Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol. 2004;16(5):441–3.

    Article  CAS  PubMed  Google Scholar 

  56. Kung YM, Hsu WH, Wu MC, Wang JW, Liu CJ, Su YC, et al. Recent advances in the pharmacological management of gastroesophageal reflux disease. Dig Dis Sci. 2017;62(12):3298–316.

    Article  CAS  PubMed  Google Scholar 

  57. Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. Cochrane Database Syst Rev. 2009;4:CD004275.

    Google Scholar 

  58. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18(6):370–3.

    Article  CAS  PubMed  Google Scholar 

  59. Zhao F, Wang S, Liu L, Wang Y. Comparative effectiveness of histamine-2 receptor antagonists as short-term therapy for gastro-esophageal reflux disease: a network meta-analysis. Int J Clin Pharmacol Ther. 2016;54(10):761–70.

    Article  CAS  PubMed  Google Scholar 

  60. Gyawali CP. Proton pump inhibitors in gastroesophageal reflux disease: friend or foe. Curr Gastroenterol Rep. 2017;19(9):46.

    Article  PubMed  Google Scholar 

  61. Larsson H, Carlsson E, Junggren U, Olbe L, Sjostrand SE, Skanberg I, et al. Inhibition of gastric acid secretion by omeprazole in the dog and rat. Gastroenterology. 1983;85(4):900–7.

    Article  CAS  PubMed  Google Scholar 

  62. Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov. 2003;2(2):132–9.

    Article  CAS  PubMed  Google Scholar 

  63. Klinkenberg-Knol EC, Jansen JM, Festen HP, Meuwissen SG, Lamers CB. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet (London, England). 1987;1(8529):349–51.

    Article  CAS  Google Scholar 

  64. Lauritsen K, Rune SJ, Bytzer P, Kelbaek H, Jensen KG, Rask-Madsen J, et al. Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial. N Engl J Med. 1985;312(15):958–61.

    Article  CAS  PubMed  Google Scholar 

  65. Walan A, Bader JP, Classen M, Lamers CB, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med. 1989;320(2):69–75.

    Article  CAS  PubMed  Google Scholar 

  66. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet. 1996;31(1):9–28.

    Article  CAS  PubMed  Google Scholar 

  67. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095.

    Google Scholar 

  68. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Lam SK, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol. 2005;11(26):4067–77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Labenz J, Malfertheiner P. Treatment of uncomplicated reflux disease. World J Gastroenterol. 2005;11(28):4291–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–810.

    Article  CAS  PubMed  Google Scholar 

  71. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut Liver. 2017;11(1):27–37.

    Article  CAS  PubMed  Google Scholar 

  72. De Graef J, Woussen-Colle MC. Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs. Gastroenterology. 1986;91(2):333–7.

    Article  PubMed  Google Scholar 

  73. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy. 1997;17(1):22–37.

    CAS  PubMed  Google Scholar 

  74. Howden CW. Review article: immediate-release proton-pump inhibitor therapy–potential advantages. Aliment Pharmacol Ther. 2005;22(Suppl 3):25–30.

    Article  CAS  PubMed  Google Scholar 

  75. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;21(12):1467–74.

    Article  CAS  PubMed  Google Scholar 

  76. Howden CW, Ballard ED, Koch FK, Gautille TC, Bagin RG. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. J Clin Gastroenterol. 2009;43(4):323–6.

    Article  PubMed  Google Scholar 

  77. Walker D, Ng Kwet Shing R, Jones D, Gruss HJ, Regula J. Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec. PLoS One. 2015;10(2):e0116308.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  78. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006;4(12):1452–8.

    Article  CAS  PubMed  Google Scholar 

  79. Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther. 2003;18(6):559–68.

    Article  CAS  PubMed  Google Scholar 

  80. Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther. 2001;15(11):1729–36.

    Article  CAS  PubMed  Google Scholar 

  81. Klok RM, Postma MJ, van Hout BA, Brouwers JR. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther. 2003;17(10):1237–45.

    Article  CAS  PubMed  Google Scholar 

  82. Mathews S, Reid A, Tian C, Cai Q. An update on the use of pantoprazole as a treatment for gastroesophageal reflux disease. Clin Exp Gastroenterol. 2010;3:11–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs. 2003;63(1):101–33.

    Article  CAS  PubMed  Google Scholar 

  84. Simon B, Muller P, Pascu O, Gatz G, Sander P, Huber R, et al. Intra-oesophageal pH profiles and pharmacokinetics of pantoprazole and esomeprazole: a crossover study in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2003;15(7):791–9.

    CAS  PubMed  Google Scholar 

  85. Mulder CJJ, Westerveld BD, Smit JM, Pool MO, Otten MH, Tan TG, et al. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial. Eur J Gastroen Hepat. 2002;14(6):649–56.

    Article  CAS  Google Scholar 

  86. Thomson A. Impact of PPIs on patient focused symptomatology in GERD. Ther Clin Risk Manag. 2008;4(6):1185–200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Scholten T, Teutsch I, Bohuschke M, Gatz G. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Clin Drug Invest. 2007;27(4):287–96.

    Article  CAS  Google Scholar 

  88. Morelli G, Chen H, Rossiter G, Rege B, Lu Y. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment Pharmacol Ther. 2011;33(7):845–54.

    Article  CAS  PubMed  Google Scholar 

  89. Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, et al. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis – the results of two double-blind studies. Aliment Pharmacol Ther. 2011;33(2):203–12.

    Article  CAS  PubMed  Google Scholar 

  90. Thoring M, Hedenstrom H, Eriksson LS. Rapid effect of lansoprazole on intragastric pH: a crossover comparison with omeprazole. Scand J Gastroenterol. 1999;34(4):341–5.

    Article  CAS  PubMed  Google Scholar 

  91. Baldi F, Malfertheiner P. Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor. Digestion. 2003;67(1–2):1–5.

    Article  CAS  PubMed  Google Scholar 

  92. Wu MS, Tan SC, Xiong T. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2013;38(2):190–201.

    Article  CAS  PubMed  Google Scholar 

  93. Hershcovici T, Jha LK, Fass R. Dexlansoprazole MR: a review. Ann Med. 2011;43(5):366–74.

    Article  CAS  PubMed  Google Scholar 

  94. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor–evidence for dosing flexibility. Aliment Pharmacol Ther. 2009;29(8):824–33.

    Article  CAS  PubMed  Google Scholar 

  95. Fass R, Johnson DA, Orr WC, Han C, Mody R, Stern KN, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011;106(3):421–31.

    Article  CAS  PubMed  Google Scholar 

  96. Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez MC. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012;10(3):247–53.

    Article  CAS  PubMed  Google Scholar 

  97. Inadomi JM, Jamal R, Murata GH, Hoffman RM, Lavezo LA, Vigil JM, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121(5):1095–100.

    Article  CAS  PubMed  Google Scholar 

  98. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003;98(9):1940–4.

    Article  CAS  PubMed  Google Scholar 

  99. Tsuzuki T, Okada H, Kawahara Y, Takenaka R, Nasu J, Ishioka H, et al. Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. World J Gastroenterol. 2011;17(11):1480–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003;98(12):2616–20.

    Article  CAS  PubMed  Google Scholar 

  101. Miner PB Jr, McKean LA, Gibb RD, Erasala GN, Ramsey DL, McRorie JW. Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors. Aliment Pharmacol Ther. 2010;31(8):846–51.

    CAS  PubMed  Google Scholar 

  102. Miehlke S, Lobe S, Madisch A, Kuhlisch E, Laass M, Grossmann D, et al. Intragastric acidity during administration of generic omeprazole or esomeprazole – a randomised, two-way crossover study including CYP2C19 genotyping. Aliment Pharm Therap. 2011;33(4):471–6.

    Article  CAS  Google Scholar 

  103. Kushner PR, Peura DA. Review of proton pump inhibitors for the initial treatment of heartburn: is there a dose ceiling effect? Adv Ther. 2011;28(5):367–88.

    Article  CAS  PubMed  Google Scholar 

  104. Armstrong D, Talley NJ, Lauritsen K, Moum B, Lind T, Tunturi-Hihnala H, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004;20(4):413–21.

    Article  CAS  PubMed  Google Scholar 

  105. Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol. 2006;4(1):50–6.

    Article  CAS  PubMed  Google Scholar 

  106. Fass R, Murthy U, Hayden CW, Malagon IB, Pulliam G, Wendel C, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther. 2000;14(12):1595–603.

    Article  CAS  PubMed  Google Scholar 

  107. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55(10):1398–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Habu Y, Maeda K, Kusuda T, Yoshino T, Shio S, Yamazaki M, et al. “Proton-pump inhibitor-first” strategy versus “step-up” strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan. J Gastroenterol. 2005;40(11):1029–35.

    Article  CAS  PubMed  Google Scholar 

  109. Mine S, Iida T, Tabata T, Kishikawa H, Tanaka Y. Management of symptoms in step-down therapy of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2005;20(9):1365–70.

    Article  CAS  PubMed  Google Scholar 

  110. Bjornsson E, Abrahamsson H, Simren M, Mattsson N, Jensen C, Agerforz P, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24(6):945–54.

    Article  CAS  PubMed  Google Scholar 

  111. MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. Integr Pharm Res Pract. 2018;7:41–52.

    Article  PubMed  PubMed Central  Google Scholar 

  112. O’Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (London, England). 2009;374(9694):989–97.

    Article  CAS  Google Scholar 

  113. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909–17.

    Article  CAS  PubMed  Google Scholar 

  114. Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology. 2017;153(1):35–48.

    Article  CAS  PubMed  Google Scholar 

  115. Yang YX. Chronic proton pump inihibitor therapy and calcium metabolism. Curr Gastroenterol Rep. 2012;14(6):473–9.

    Article  PubMed  PubMed Central  Google Scholar 

  116. O’Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118(7):778–81.

    Article  PubMed  CAS  Google Scholar 

  117. Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21–5.

    Article  CAS  PubMed  Google Scholar 

  118. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947–53.

    Article  CAS  PubMed  Google Scholar 

  119. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010;170(9):765–71.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010;139(1):93–101.

    Article  PubMed  Google Scholar 

  121. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.

    Article  PubMed  PubMed Central  Google Scholar 

  122. Fraser LA, Leslie WD, Targownik LE, Papaioannou A, Adachi JD, Group CR. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013;24(4):1161–8.

    Article  CAS  PubMed  Google Scholar 

  123. Khalili H, Huang ES, Jacobson BC, Camargo CA, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18; quiz 19

    Article  CAS  PubMed  Google Scholar 

  125. Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27(1):339–47.

    Article  CAS  PubMed  Google Scholar 

  126. Targownik LE, Lix LM, Leung S, Leslie WD. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010;138(3):896–904.

    Article  CAS  PubMed  Google Scholar 

  127. Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112(1):95–101.

    Article  CAS  PubMed  Google Scholar 

  128. Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361–9.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Freedberg DE, Kim LS, Yang YX. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–15.

    Article  CAS  PubMed  Google Scholar 

  130. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–46.

    Article  PubMed  PubMed Central  Google Scholar 

  131. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27(10):3153–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Antoniou T, Macdonald EM, Hollands S, Gomes T, Mamdani MM, Garg AX, et al. Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open. 2015;3(2):E166–71.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Klatte DCF, Gasparini A, Xu H, de Deco P, Trevisan M, Johansson ALV, et al. Association between proton pump inhibitor use and risk of progression of chronic kidney disease. Gastroenterology. 2017;153(3):702–10.

    Article  CAS  PubMed  Google Scholar 

  134. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L, Thein H, et al. Proton pump inhibitors and acute interstitial nephritis: report and analysis of 15 cases. Nephrology (Carlton). 2006;11(5):381–5.

    Article  CAS  PubMed  Google Scholar 

  136. Sierra F, Suarez M, Rey M, Vela MF. Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther. 2007;26(4):545–53.

    Article  CAS  PubMed  Google Scholar 

  137. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001;15(3):511–21.

    Article  CAS  PubMed  Google Scholar 

  138. Theisen J, Nehra D, Citron D, Johansson J, Hagen JA, Crookes PF, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4(1):50–4.

    Article  CAS  PubMed  Google Scholar 

  139. Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998;12(1):99–104.

    Article  CAS  PubMed  Google Scholar 

  140. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.

    Article  CAS  PubMed  Google Scholar 

  141. Lewis SJ, Franco S, Young G, O’Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther. 1996;10(4):557–61.

    Article  CAS  PubMed  Google Scholar 

  142. Wilson KH, Sheagren JN, Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis. 1985;151(2):355–61.

    Article  CAS  PubMed  Google Scholar 

  143. Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a Crossover Trial. Gastroenterology. 2015;149(4):883–5.e9.

    Article  CAS  PubMed  Google Scholar 

  144. Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome. 2014;2:42.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol. 2012;107(7):1001–10.

    Article  CAS  PubMed  Google Scholar 

  146. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9.

    Article  CAS  PubMed  Google Scholar 

  147. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170(9):784–90.

    Article  PubMed  Google Scholar 

  148. Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile infection: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(6):784–91.

    Article  PubMed  PubMed Central  Google Scholar 

  149. Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012;87(7):636–42.

    Article  PubMed  PubMed Central  Google Scholar 

  150. Leonard AD, Ho KM, Flexman J. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study. Intern Med J. 2012;42(5):591–4.

    Article  CAS  PubMed  Google Scholar 

  151. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut. 1992;33(5):617–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–60.

    Article  CAS  PubMed  Google Scholar 

  153. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167(9):950–5.

    Article  CAS  PubMed  Google Scholar 

  154. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301(20):2120–8.

    Article  CAS  PubMed  Google Scholar 

  155. Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2014;63(4):552–8.

    Article  CAS  PubMed  Google Scholar 

  156. Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–77.

    Article  CAS  PubMed  Google Scholar 

  157. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol. 2012;5(3):337–44.

    Article  CAS  PubMed  Google Scholar 

  158. Hermos JA, Young MM, Fonda JR, Gagnon DR, Fiore LD, Lawler EV. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed. Clin Infect Dis. 2012;54(1):33–42.

    Article  CAS  PubMed  Google Scholar 

  159. Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  160. Badiola N, Alcalde V, Pujol A, Münter LM, Multhaup G, Lleó A, et al. The proton-pump inhibitor lansoprazole enhances amyloid beta production. PLoS One. 2013;8(3):e58837.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  161. Haenisch B, von Holt K, Wiese B, Prokein J, Lange C, Ernst A, et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci. 2015;265(5):419–28.

    Article  PubMed  Google Scholar 

  162. Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73(4):410–6.

    Article  PubMed  Google Scholar 

  163. Taipale H, Tolppanen AM, Tiihonen M, Tanskanen A, Tiihonen J, Hartikainen S. No association between proton pump inhibitor use and risk of Alzheimer’s disease. Am J Gastroenterol. 2017;112(12):1802–8.

    Article  CAS  PubMed  Google Scholar 

  164. Lochhead P, Hagan K, Joshi AD, Khalili H, Nguyen LH, Grodstein F, et al. Association between proton pump inhibitor use and cognitive function in women. Gastroenterology. 2017;153(4):971–9.e4.

    Article  CAS  PubMed  Google Scholar 

  165. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–42.

    Article  CAS  PubMed  Google Scholar 

  166. Bezwoda W, Charlton R, Bothwell T, Torrance J, Mayet F. The importance of gastric hydrochloric acid in the absorption of nonheme food iron. J Lab Clin Med. 1978;92(1):108–16.

    CAS  PubMed  Google Scholar 

  167. Stewart CA, Termanini B, Sutliff VE, Serrano J, Yu F, Gibril F, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998;12(1):83–98.

    Article  CAS  PubMed  Google Scholar 

  168. Hutchinson C, Geissler CA, Powell JJ, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56(9):1291–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Sarzynski E, Puttarajappa C, Xie Y, Grover M, Laird-Fick H. Association between proton pump inhibitor use and anemia: a retrospective cohort study. Dig Dis Sci. 2011;56(8):2349–53.

    Article  CAS  PubMed  Google Scholar 

  170. Lam JR, Schneider JL, Quesenberry CP, Corley DA. Proton pump inhibitor and histamine-2 receptor antagonist use and iron deficiency. Gastroenterology. 2017;152(4):821–9.e1.

    Article  CAS  PubMed  Google Scholar 

  171. Koop H, Bachem MG. Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol. 1992;14(4):288–92.

    Article  CAS  PubMed  Google Scholar 

  172. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–6.

    Article  CAS  PubMed  Google Scholar 

  173. Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, Srivali N, Edmonds PJ, Ungprasert P, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015;37(7):1237–41.

    Article  CAS  PubMed  Google Scholar 

  174. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther. 2012;36(5):405–13.

    Article  CAS  PubMed  Google Scholar 

  175. Bassey OO. Pregnancy heartburn in Nigerians and Caucasians with theories about aetiology based on manometric recordings from the oesophagus and stomach. Br J Obstet Gynaecol. 1977;84(6):439–43.

    Article  CAS  PubMed  Google Scholar 

  176. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann Med. 1995;27(1):67–70.

    Article  CAS  PubMed  Google Scholar 

  177. Rey E, Rodriguez-Artalejo F, Herraiz MA, Sanchez P, Alvarez-Sanchez A, Escudero M, et al. Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol. 2007;102(11):2395–400.

    Article  PubMed  Google Scholar 

  178. Marrero JM, Goggin PM, de Caestecker JS, Pearce JM, Maxwell JD. Determinants of pregnancy heartburn. Br J Obstet Gynaecol. 1992;99(9):731–4.

    Article  CAS  PubMed  Google Scholar 

  179. Richter JE. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am. 2003;32(1):235–61.

    Article  PubMed  Google Scholar 

  180. Tsai CC, Tey SL, Chang LC, Su YT, Lin KJ, Huang SC. Estradiol mediates relaxation of porcine lower esophageal sphincter. Steroids. 2018;136:56–62.

    Article  CAS  PubMed  Google Scholar 

  181. Ali RA, Egan LJ. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol. 2007;21(5):793–806.

    Article  PubMed  Google Scholar 

  182. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005;22(9):749–57.

    Article  CAS  PubMed  Google Scholar 

  183. Richter JE. Heartburn, nausea, and vomiting during pregnancy. Pregnancy in gastrointestinal disorders, ACG Monograph American College of Physicians. 2007, p. 18–25.

    Google Scholar 

  184. Ching CK, Lam SK. Antacids. Indications and limitations. Drugs. 1994;47(2):305–17.

    Article  CAS  PubMed  Google Scholar 

  185. Phupong V, Hanprasertpong T. Interventions for heartburn in pregnancy. Cochrane Database Syst Rev. 2015;(9):CD011379.

    Google Scholar 

  186. Eltonsy S, Martin B, Ferreira E, Blais L. Systematic procedure for the classification of proven and potential teratogens for use in research. Birth Defects Res A Clin Mol Teratol. 2016;106(4):285–97.

    Article  CAS  PubMed  Google Scholar 

  187. Undeland KA, Hausken T, Svebak S, Aanderud S, Berstad A. Wide gastric antrum and low vagal tone in patients with diabetes mellitus type 1 compared to patients with functional dyspepsia and healthy individuals. Dig Dis Sci. 1996;41(1):9–16.

    Article  CAS  PubMed  Google Scholar 

  188. Ruigómez A, García Rodríguez LA, Cattaruzzi C, Troncon MG, Agostinis L, Wallander MA, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol. 1999;150(5):476–81.

    Article  PubMed  Google Scholar 

  189. Larson JD, Patatanian E, Miner PB, Rayburn WF, Robinson MG. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol. 1997;90(1):83–7.

    Article  CAS  PubMed  Google Scholar 

  190. Parker S, Schade RR, Pohl CR, Gavaler JS, Van Thiel DH. Prenatal and neonatal exposure of male rat pups to cimetidine but not ranitidine adversely affects subsequent adult sexual functioning. Gastroenterology. 1984;86(4):675–80.

    CAS  PubMed  Google Scholar 

  191. Savarino V, Giusti M, Scalabrini P, Bessarione D, Magnolia MR, Percario G, et al. Famotidine has no significant effect on gonadal function in man. Gastroenterol Clin Biol. 1988;12(1):19–22.

    CAS  PubMed  Google Scholar 

  192. Morton DM. Pharmacology and toxicology of nizatidine. Scand J Gastroenterol Suppl. 1987;136:1–8.

    Article  CAS  PubMed  Google Scholar 

  193. Nikfar S, Abdollahi M, Moretti ME, Magee LA, Koren G. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci. 2002;47(7):1526–9.

    Article  CAS  PubMed  Google Scholar 

  194. Gill SK, O’Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol. 2009;104(6):1541–5; quiz 0, 6

    Article  CAS  PubMed  Google Scholar 

  195. Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363(22):2114–23.

    Article  CAS  PubMed  Google Scholar 

  196. Feldman M, Burton ME. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med. 1990;323(24):1672–80.

    Article  CAS  PubMed  Google Scholar 

  197. Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  198. Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin Drug Investig. 2009;29(1):35–50.

    Article  CAS  PubMed  Google Scholar 

  199. Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors. Clin Pharmacokinet. 2010;49(8):509–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA

    Charles Muller

  2. Department of Medicine, University of Chicago, Chicago, IL, USA

    Natalie Tapaskar

  3. Center for Esophageal Diseases, Department of Medicine, Section of Gastroenterology, Hepatology, and Nutrition, University of Chicago, Chicago, IL, USA

    Robert T. Kavitt

  4. University of Chicago Medicine, Chicago, IL, USA

    Robert T. Kavitt

Authors
  1. Charles Muller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalie Tapaskar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert T. Kavitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert T. Kavitt .

Editor information

Editors and Affiliations

  1. University of North Carolina, Chapel Hill, NC, USA

    Marco G. Patti

  2. University of North Carolina, Chapel Hill, NC, USA

    Marco Di Corpo

  3. University of Buenos Aires, Buenos Aires, Argentina

    Francisco Schlottmann

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Muller, C., Tapaskar, N., Kavitt, R.T. (2020). Medical Treatment of GERD. In: Patti, M., Di Corpo, M., Schlottmann, F. (eds) Foregut Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-27592-1_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27592-1_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27591-4

  • Online ISBN: 978-3-030-27592-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation